Ripple vs Chainalysis: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Ripple and Chainalysis.
Ripple
Blockchain-based global payment network and issuer of the XRP digital asset.
IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Crypto-adjacent with cycle sensitivity; ISO/NSO options; liquidity tracks market conditions
Chainalysis
Blockchain analytics platform that traces cryptocurrency flows to detect illicit activity, provide compliance tools, and support law enforcement investigations.
No near-term IPO expected. Secondary trades at a discount vs last round — exercise timing requires caution. Company likely 2028+ at earliest; patient equity required.
Crypto-adjacent with cycle sensitivity; ISO/NSO options; secondary discount vs primary — price discovery ongoing; liquidity tracks market conditions
Key differences for employees
Equity structure
Ripple grants ISO/NSO with strike prices ranging from $8–$20 depending on your grant year. Chainalysis grants ISO/NSO with strike prices from $18–$30.
Secondary market premium
The secondary market is pricing Ripple at a +3% premium over its last primary round ($11.3B → $11.6B). Chainalysis trades at +-14% over its last round ($8.6B → $7.4B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Ripple runs at $0.6B ARR, growing +25% YoY (solid). Chainalysis runs at $0.3B ARR, growing +20% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Ripple: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Chainalysis: No near-term IPO expected. Secondary trades at a discount vs last round — exercise timing requires caution. Company likely 2028+ at earliest; patient equity required.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.